Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.
Hosted on MSN17d
Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs(Reuters) - Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using ...
On the last day of 2024, Lexington’s Valo Health Inc. also shared that its Phase 2 trial of OPL-0401 in patients with diabetic retinopathy did not meet its primary or secondary end ...
Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...
Valo Health has said it will no longer develop a drug candidate for diabetic retinopathy on its own after a phase 2 readout – but will seek a partner to take the programme forward. The start-up ...
Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop ...
Novo Nordisk NOVO.B2.14%increase; green up pointing triangle expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human ...
Zacks.com on MSN16d
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to BuyNVO Expands Collaboration Agreement With Valo Health In the last press release, Novo Nordisk announced expanding its partnership with Valo, leveraging the latter’s extensive human dataset and ...
Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...
Lexington: Novo Nordisk A/S and Valo Health, Inc. have announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback